Kite Pharma, Inc. (NASDAQ:KITE) Sees Significantly Higher Trading Volume

The stock decreased 0.06% or $0.1 during the last trading session, reaching $177.95.

About 264 shares traded.

Kite Pharma (NASDAQ:KITE) last posted its quarterly earnings data on Tuesday, August 8th. It has outperformed by 38.77% the S&P500. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The company has market cap of $10.18 billion. It now has negative earnings. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. As of quarter end Wildcat Capital Management, LLC had bought a total of 51,950 shares growing its position 2.2%. Voloridge Investment Management, LLC now owns 166,843 shares worth $17,297,000. Moreover, Muhlenkamp & Co Inc has 3.51% invested in the company for 504,379 shares. The California-based Scge Management L.P. has invested 1.98% in the stock. Deerfield Management Co, a New York-based fund reported 2.01 million shares. Following the completion of the transaction, the director now owns 155,017 shares of the company’s stock, valued at approximately $13,095,836.16. 2,634,903 shares of the company were exchanged. It has underperformed by 16.70% the S&P500. The biopharmaceutical company reported ($1.94) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.97) by $0.03.

Several research analysts have recently commented on KITE shares.

These funds have also shifted positions in (KITE).

Here is the rundown on market activity for Kite Pharma, Inc. Kcg Holdg Incorporated has invested 0.03% in Kite Pharma Inc (NASDAQ:KITE).

Tocqueville Asset Limited Partnership has 57,965 shares for 0.03% of their portfolio. (NASDAQ:KITE). Timothy L. Moore, EVP disclosed the sale of 6,000 shares of (KITE). Federated Inc Pa stated it has 10,000 shares or 0% of all its holdings. Seabridge Inv Advisors holds 0% or 40 shares. Vanguard Grp invested in 3.15M shares or 0.01% of the stock. Rice Hall James And Assocs Ltd Llc accumulated 0.1% or 45,402 shares. Jennison Associate holds 622,607 shares.

Gilead Sciences Inc has agreed to buy Kite Pharma Inc for about $11 billion in an all-cash deal, the Wall Street Journal reported on Monday, citing people familiar with the matter. Ubs Asset Americas holds 0.02% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 404,137 shares. Eventide Asset Ltd Limited Liability Company has invested 0.37% in Kite Pharma Inc (NASDAQ:KITE). Sandy Spring Commercial Bank owns 1,100 shares. Ulta Salon Cosmetcs & Frag I (NASDAQ:ULTA) was raised too. Therefore 77% are positive.

Ratings analysis reveals 60% of Kite Pharma’s analysts are positive. Canaccord Genuity set a $115.00 price objective on shares of Kite Pharma and gave the company a “buy” rating in a research note on Tuesday, June 27th. The firm has “Buy” rating given on Friday, April 21 by Jefferies. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Buy” rating given on Monday, June 26 by Cowen & Co. The stock has “Market Perform” rating by Wells Fargo on Wednesday, February 22. The stock of Kite Pharma Inc (NASDAQ:KITE) earned “Mkt Perform” rating by FBR Capital on Thursday, September 3. On August 28 the company was downgraded from “Buy” to “Hold” by SunTrust Robinson Humphrey. The firm has “Buy” rating given on Wednesday, January 4 by TH Capital. The firm has “Neutral” rating given on Thursday, August 27 by Bank of America.

Since March 1, 2017, it had 5 buys, and 12 sales for $6.87 million activity. Jpmorgan Chase & Commerce holds 0.03% or 2.99 million shares in its portfolio. 20,000 shares were sold by Chang David D, worth $1.63M. The value of the total investment in Kite Pharma, Inc. increased from $7,610,000 to $9,638,000 a change of 26.6% quarter to quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *